NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
16
MEDIF Quote, Financials, Valuation and Earnings
Last price:
$0.04
Seasonality move
:
14.13%
Day range:
$0.04 - $0.04
52-week range:
$0.04 - $0.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.60x
P/B ratio:
0.53x
Volume:
291.5K
Avg. volume:
171.4K
1-year change:
-10.21%
Market cap:
$17.7M
Revenue:
$24.5M
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
$8.9M | -- | 15.54% | -- | -- |
|
AUPH
Aurinia Pharmaceuticals
|
$57.7M | $0.02 | 32.93% | -24.07% | -- |
|
EDSA
Edesa Biotech
|
-- | -- | -- | -- | $20.50 |
|
EPIX
ESSA Pharma
|
-- | -$0.20 | -- | -28.8% | -- |
|
LEXX
Lexaria Bioscience
|
$100K | -- | -31.04% | -- | -- |
|
XENE
Xenon Pharmaceuticals
|
-- | -$0.79 | -- | -28.14% | $57.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
$0.04 | -- | $17.7M | -- | $0.00 | 0% | 0.60x |
|
AUPH
Aurinia Pharmaceuticals
|
$9.03 | -- | $1.3B | -- | $0.00 | 0% | 5.92x |
|
EDSA
Edesa Biotech
|
$1.65 | $20.50 | $5.7M | -- | $0.00 | 0% | 16.05x |
|
EPIX
ESSA Pharma
|
$1.60 | -- | $71M | -- | $0.00 | 0% | -- |
|
LEXX
Lexaria Bioscience
|
$2.23 | -- | $38.9M | -- | $0.00 | 0% | 59.30x |
|
XENE
Xenon Pharmaceuticals
|
$38.69 | $57.67 | $2.9B | -- | $0.00 | 0% | 222.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
1.25% | -1.532 | 2.06% | 1.84x |
|
AUPH
Aurinia Pharmaceuticals
|
-- | 0.341 | -- | 4.90x |
|
EDSA
Edesa Biotech
|
-- | 0.099 | -- | -- |
|
EPIX
ESSA Pharma
|
-- | 0.357 | -- | -- |
|
LEXX
Lexaria Bioscience
|
-- | 5.584 | -- | 55.84x |
|
XENE
Xenon Pharmaceuticals
|
-- | 0.783 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
$2.3M | -$2M | -22.42% | -23.29% | -25.91% | -$516.2K |
|
AUPH
Aurinia Pharmaceuticals
|
$61.7M | $11.7M | -5.99% | -5.99% | 23.63% | $16.9M |
|
EDSA
Edesa Biotech
|
-- | -$967.2K | -- | -- | -- | -$967K |
|
EPIX
ESSA Pharma
|
-- | -$7M | -- | -- | -- | -$3.4M |
|
LEXX
Lexaria Bioscience
|
$84K | -$1.7M | -93.31% | -93.31% | -2074.9% | -$1.3M |
|
XENE
Xenon Pharmaceuticals
|
-- | -$73.7M | -- | -- | -- | -$51.7M |
MediPharm Labs vs. Competitors
-
Which has Higher Returns MEDIF or AUPH?
Aurinia Pharmaceuticals has a net margin of -28.31% compared to MediPharm Labs's net margin of 21.17%. MediPharm Labs's return on equity of -23.29% beat Aurinia Pharmaceuticals's return on equity of -5.99%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M AUPHAurinia Pharmaceuticals91.1% $0.10 $388M -
What do Analysts Say About MEDIF or AUPH?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 20%. Given that Aurinia Pharmaceuticals has higher upside potential than MediPharm Labs, analysts believe Aurinia Pharmaceuticals is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 AUPHAurinia Pharmaceuticals0 0 0 -
Is MEDIF or AUPH More Risky?
MediPharm Labs has a beta of 0.974, which suggesting that the stock is 2.559% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.752%.
-
Which is a Better Dividend Stock MEDIF or AUPH?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Aurinia Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or AUPH?
MediPharm Labs quarterly revenues are $7.2M, which are smaller than Aurinia Pharmaceuticals quarterly revenues of $67.8M. MediPharm Labs's net income of -$2M is lower than Aurinia Pharmaceuticals's net income of $14.4M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Aurinia Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.60x versus 5.92x for Aurinia Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.60x -- $7.2M -$2M AUPHAurinia Pharmaceuticals5.92x -- $67.8M $14.4M
-
Which has Higher Returns MEDIF or EDSA?
Edesa Biotech has a net margin of -28.31% compared to MediPharm Labs's net margin of --. MediPharm Labs's return on equity of -23.29% beat Edesa Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M EDSAEdesa Biotech-- -$0.29 -- -
What do Analysts Say About MEDIF or EDSA?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech has an analysts' consensus of $20.50 which suggests that it could grow by 1142.42%. Given that Edesa Biotech has higher upside potential than MediPharm Labs, analysts believe Edesa Biotech is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 EDSAEdesa Biotech0 0 0 -
Is MEDIF or EDSA More Risky?
MediPharm Labs has a beta of 0.974, which suggesting that the stock is 2.559% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.837%.
-
Which is a Better Dividend Stock MEDIF or EDSA?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or EDSA?
MediPharm Labs quarterly revenues are $7.2M, which are larger than Edesa Biotech quarterly revenues of --. MediPharm Labs's net income of -$2M is lower than Edesa Biotech's net income of -$962.1K. Notably, MediPharm Labs's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.60x versus 16.05x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.60x -- $7.2M -$2M EDSAEdesa Biotech16.05x -- -- -$962.1K
-
Which has Higher Returns MEDIF or EPIX?
ESSA Pharma has a net margin of -28.31% compared to MediPharm Labs's net margin of --. MediPharm Labs's return on equity of -23.29% beat ESSA Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M EPIXESSA Pharma-- -$0.14 -- -
What do Analysts Say About MEDIF or EPIX?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 492.85%. Given that ESSA Pharma has higher upside potential than MediPharm Labs, analysts believe ESSA Pharma is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 EPIXESSA Pharma0 0 0 -
Is MEDIF or EPIX More Risky?
MediPharm Labs has a beta of 0.974, which suggesting that the stock is 2.559% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.
-
Which is a Better Dividend Stock MEDIF or EPIX?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or EPIX?
MediPharm Labs quarterly revenues are $7.2M, which are larger than ESSA Pharma quarterly revenues of --. MediPharm Labs's net income of -$2M is higher than ESSA Pharma's net income of -$6.4M. Notably, MediPharm Labs's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.60x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.60x -- $7.2M -$2M EPIXESSA Pharma-- -- -- -$6.4M
-
Which has Higher Returns MEDIF or LEXX?
Lexaria Bioscience has a net margin of -28.31% compared to MediPharm Labs's net margin of -2121.06%. MediPharm Labs's return on equity of -23.29% beat Lexaria Bioscience's return on equity of -93.31%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M LEXXLexaria Bioscience-- -$0.13 $9.7M -
What do Analysts Say About MEDIF or LEXX?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 348.43%. Given that Lexaria Bioscience has higher upside potential than MediPharm Labs, analysts believe Lexaria Bioscience is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 LEXXLexaria Bioscience0 0 0 -
Is MEDIF or LEXX More Risky?
MediPharm Labs has a beta of 0.974, which suggesting that the stock is 2.559% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.
-
Which is a Better Dividend Stock MEDIF or LEXX?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or LEXX?
MediPharm Labs quarterly revenues are $7.2M, which are larger than Lexaria Bioscience quarterly revenues of $84K. MediPharm Labs's net income of -$2M is lower than Lexaria Bioscience's net income of -$1.8M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.60x versus 59.30x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.60x -- $7.2M -$2M LEXXLexaria Bioscience59.30x -- $84K -$1.8M
-
Which has Higher Returns MEDIF or XENE?
Xenon Pharmaceuticals has a net margin of -28.31% compared to MediPharm Labs's net margin of --. MediPharm Labs's return on equity of -23.29% beat Xenon Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M XENEXenon Pharmaceuticals-- -$0.81 -- -
What do Analysts Say About MEDIF or XENE?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 49.05%. Given that Xenon Pharmaceuticals has higher upside potential than MediPharm Labs, analysts believe Xenon Pharmaceuticals is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 XENEXenon Pharmaceuticals11 0 0 -
Is MEDIF or XENE More Risky?
MediPharm Labs has a beta of 0.974, which suggesting that the stock is 2.559% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.
-
Which is a Better Dividend Stock MEDIF or XENE?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or XENE?
MediPharm Labs quarterly revenues are $7.2M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. MediPharm Labs's net income of -$2M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.60x versus 222.63x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.60x -- $7.2M -$2M XENEXenon Pharmaceuticals222.63x -- -- -$62.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 3.03% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 3.83% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 6.46% over the past day.
